

CORRECTION

Open Access



Correction to: Intracellular hypoxia measured by F-18 fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen-receptor positive breast (BRCR-D17-00693)

Aya Asano^{1†}, Shigeto Ueda^{2†}, Ichiei Kuji^{3*}, Tomohiko Yamane^{3†}, Hideki Takeuchi¹, Eiko Hirokawa², Ikuko Sugitani², Hiroko Shimada², Takahiro Hasebe⁴, Akihiko Osaki² and Toshiaki Saeki²

Correction


After the publication of this article [1], we noticed that in Fig. 2, the survival curve images (C and D, lower panel) were incorrect. The corrected Fig. 2 is presented below. The correction does not affect in any our results and conclusions.

* Correspondence: kuji@saitama-med.ac.jp

[†]Aya Asano, Shigeto Ueda and Tomohiko Yamane contributed equally to this work.

³Department of Nuclear Medicine, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1241, Japan





Author details

¹Department of Breast Oncology, Saitama Medical University Hospital, 38 Morohongo, Moroyama-machi, Irumagun, Saitama 350-0451, Japan.

²Department of Breast Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1241, Japan.

³Department of Nuclear Medicine, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1241, Japan.

⁴Department of Pathology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1241, Japan.

Published online: 05 September 2018

Reference

- Asano A, Ueda S, Kuji I, Yamane T, Takeuchi H, Hirokawa E, Sugitani I, Shimada H, Hasebe T, Osaki A, et al. Intracellular hypoxia measured by (18)F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer. *Breast Cancer Res.* 2018;20(1):78.